Sumitomo Pharma Co., Ltd.
4506.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥119,120,000 | ¥108,002,000 | ¥105,649,000 | ¥112,434,000 |
| % Growth | 10.3% | 2.2% | -6% | – |
| Cost of Goods Sold | ¥45,589,000 | ¥44,112,000 | ¥39,671,000 | ¥41,439,000 |
| Gross Profit | ¥73,531,000 | ¥63,890,000 | ¥65,978,000 | ¥70,995,000 |
| % Margin | 61.7% | 59.2% | 62.5% | 63.1% |
| R&D Expenses | ¥9,349,000 | ¥8,175,000 | ¥13,126,000 | ¥10,467,000 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥40,904,000 | ¥35,657,000 | ¥49,565,000 | ¥41,044,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | -¥12,291,000 | -¥1,921,000 |
| Operating Expenses | ¥50,253,000 | ¥43,832,000 | ¥50,400,000 | ¥49,590,000 |
| Operating Income | ¥23,278,000 | ¥20,058,000 | ¥15,578,000 | ¥21,405,000 |
| % Margin | 19.5% | 18.6% | 14.7% | 19% |
| Other Income/Exp. Net | ¥57,592,000 | -¥8,126,000 | -¥21,993,000 | ¥35,027,000 |
| Pre-Tax Income | ¥80,870,000 | ¥11,932,000 | -¥6,415,000 | ¥56,432,000 |
| Tax Expense | -¥6,784,000 | ¥726,000 | -¥8,830,000 | ¥2,984,000 |
| Net Income | ¥87,654,000 | ¥11,206,000 | ¥2,415,000 | ¥53,448,000 |
| % Margin | 73.6% | 10.4% | 2.3% | 47.5% |
| EPS | 220.63 | 28.21 | 6.08 | 134.53 |
| % Growth | 682.1% | 364% | -95.5% | – |
| EPS Diluted | 220.63 | 28.21 | 6.08 | 134.53 |
| Weighted Avg Shares Out | 397,290 | 397,290 | 397,290 | 397,290 |
| Weighted Avg Shares Out Dil | 397,290 | 397,290 | 397,290 | 397,290 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥654,000 | ¥585,000 | ¥0 | ¥15,643,000 |
| Interest Expense | ¥0 | ¥9,053,000 | ¥7,451,000 | ¥0 |
| Depreciation & Amortization | ¥5,278,000 | ¥5,203,000 | ¥5,807,000 | ¥6,066,000 |
| EBITDA | ¥86,148,000 | ¥26,188,000 | ¥5,604,000 | ¥27,471,000 |
| % Margin | 72.3% | 24.2% | 5.3% | 24.4% |